IgY-112

IgY-112 is a discovery-stage biologic therapeutic being developed by IGY Immune Technologies & Life Sciences for the treatment of celiac disease. It consists of polyclonal IgY antibodies derived from chicken egg yolks. The drug is designed to target and neutralize mucosal immune response mediators that are implicated in the pathogenesis of celiac disease. By blocking the interaction between hypersensitive or excessive mucosal immune responses and specific microbial or protein components in the small intestine, IgY-112 aims to reduce pathogenic mucosal immune activation. It is intended for oral administration, likely utilizing a capsule formulation to deliver the antibodies directly to the small intestine.